RE-CROSS by Reviscon

The first generation of cross-linked hyaluronic acid with HXL HYBRID XLink technology.

A real innovation beyond the limits of traditional viscosupplements.

RE-CROSS by Reviscon is an innovative viscosupplement for the treatment of symptomatic osteoarthritis with a single injection. It is a sterile, non-pyrogenic, clear, non-inflammatory cross-linked sodium hyaluronate that is not structured on animals, obtained by bacterial fermentation.

Thanks to a unique structure that differs from traditional cross and linear hyaluronic acid, RE-CROSS by Revisco provides an absolute dual structure -HXL Hybrid XLinkTechnologia TM to combat pain caused by osteoarthritis and other conditions, enhancing joint lubrication and reducing stress on OA joints with a high safety profile.

Single injection with a dose of 4 ml.

  • A convenient one-stop pain relief solution for patients.
  • Optimal strength for various degenerate joints such as shoulders, hips, knees, TMJ with OA.

Hyaluronic acid restores the natural functionality of the synovial fluid

  • Use of hyaluronic acid dependent supplementation proved to be a successful method in restoring the innate characteristics of synovial fluid in patients withosteoartritis.
  • This treatment can offer permanent pain relief, improve mobility and extend the interval before patients need joint replacement surgery.
  • HA injections increase the viscoelasticity of the synovial fluid, restoring its lubricating, absorbing and filtering properties.
  • The protective coating of HA is re-established over the inner surface of the joint.
  • HA reduces synovial inflammation.
  • HA masks the nociceptors in the joint and thus relieves pain.

RECROSS by Reviscon isdesigned to secure and dispersive and cohesive characteristics within the joint.

Cross-linked hyaluronic acid with cohesive properties

Mechanical strength – Improved shock absorption.

Crosswise connected hyaluronic acid (CHA) in RE-CROSS By Reviscon effectively reduces friction, improves joint mobility and provides relief of pain. CHA exhibits a significant degree of viscoelasticity, allowing it to replicate the viscoelastic attributes of healthy synovial fluid.

This unique quality positions it as an excellent choice for improving shock absorption, lubrication and cushioning of the joint, especially in cases of articular cartilage damage.

Long lasting durability – Specially formulated CHA means durability.

CHA has a longer half-life in the joint compared to unbound hyaluronic acid (NonCHA), offering prolonged relief and reducing the frequency of injections.

Pain reduction – Less pain in the damaged joint.

CHA can relieve pain which originates from damaged cartilage by improving joint biomechanics. Often, pain is the result of mechanical problems in the joint due to cartilage damage, and the biomechanical characteristics of CHA are adept at addressing this problem.

Unbound hyaluronic acid with dispersive properties

Coating and protection

Unbound hyaluronic acid (Non-CHA) is formulated establish a protective and lubricating barrier on the surface of the joint. This layer of coating serves to protect damaged cartilage and joint surfaces, reducing additional friction i mehaničko opterećenje na zahvaćenom području.

Support for the recovery process – Treatment: Direct effect.

Non-CHA can help minimize further damage to existing cartilage and promote a healthier joint environment. It may also have anti-inflammatory properties, offering potential benefits for joints affected by inflammation due to cartilage damage.

Improved joint lubricity – Improved lubrication for better mobility.

Non-CHA provides effective joint lubrication, resulting in reduced friction and reduced stress – wear and tear on damaged cartilage. This advantage becomes especially pronounced when cartilage damage leads to an uneven joint surface, as it promotes smoother joint mobility.

Viscosupplement Model RE-CROSS by Reviscon
Substance Cross-linked sodium hyaluronate
Concentration 88mg HA (2.2%)
Quantity 4 ml
Doseage 1/Single Dose
Origin Bacterial fermentation
Molecular mass App. 1-3 M Da

RE-CROSS by Reviscon is a pre-filled syringe containing a cross-linked viscoelastic solution of sodium hyaluronate for intra-articular administration. Reviscon’s RE-CROSS consists of 4.0 mL of viscoelastic solution in a 5.0 mL single-use syringe. RE-CROSS by Reviscon is a sterile, non-pyrogenic, clear, non-inflammatory cross-linked sodium hyaluronate dissolved in buffered saline. Sodium hyaluronate is obtained by bacterial fermentation and is cross-linked with a very small amount of cross-linking agent. RE-CROSS by Reviscon contains mildly cross-linked sodium hyaluronate, sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate and water for injections.

Indications: RE-CROSS by Reviscon is indicated as a viscoelastic supplement or replacement for synovial fluid in human joints. Reviscon’s RE-CROSS is well suited for the treatment of symptoms of human joint dysfunction such as osteoarthritis; non-surgical treatment options for knee and hip osteoarthritis (OA) · treatment of symptoms associated with temporomandibular joint (TMJ) dysfunctions. · to treat chronic shoulder pain associated with osteoarthritis or rotator cuff damage. · intra- and postoperative intra-articular injection in patients undergoing joint arthroscopy. RE-CROSS-a by Reviscon acts for lubrication and mechanical support.

Contraindications: Do not administer to patients with known hypersensitivity to any of the materials contained in RE-CROSS by Reviscon injections. Intra-articular injections are contraindicated in cases of existing infections or skin diseases in the area of the injection site in order to reduce the potential for the development of septic arthritis.

For more complete safety information, see the package insert. We cannot guarantee the accuracy or comprehensiveness of any information provided, and we cannot guarantee its suitability for individual user situations. This brochure is for informational purposes only. Please note that this medicinal product is a regulated health product, bearing the CE mark according to the CE1984 regulation and registered under 93/42 EEC (MDD).